Topical colchicine selection of keratinocytes transduced with the multidrug resistance gene (MDR1) can sustain and enhance transgene expression in vivo.
Topical colchicine selection of keratinocytes transduced with the multidrug resistance gene (MDR1) can sustain and enhance transgene expression in vivo.
复制标题
对转导多药耐药基因 (MDR1) 的角质形成细胞进行局部秋水仙碱选择可以维持和增强体内转基因表达。
DOI:
10.1073/pnas.192247899
复制
发表时间:
2002
影响因子:
11.1
通讯作者:
Vogel,JC
中科院分区:
文献类型:
--
作者:
Pfutzner,W;Terunuma,A;Tock,CL;Snead,EK;Kolodka,TM;Gottesman,MM;Taichman,L;Vogel,JC
For skin gene therapy, achieving prolonged high-level gene expression in a significant percentage of keratinocytes (KC) is difficult because we cannot selectively target KC stem cells. We now demonstrate that topical colchicine treatment can be used to select,in vivo, KC progenitor cells transduced with the multidrug resistance gene (MDR1). When human skin equivalents containingMDR1-transduced KC were grafted onto immunocompromised mice, topical colchicine treatments significantly increased (7-fold) the percentage of KC expressing MDR1, compared to vehicle-treated controls, for up to 24 wk. Topical colchicine treatment also significantly enhanced the amount of MDR1 protein expressed in individual KC. Furthermore, quantitative real-time PCR analysis ofMDR1transgene copy number demonstrates that topical colchicine treatment selects and enriches for KC progenitor cells in the skin that contain and express MDR1. For clinical skin gene therapy applications, thisin vivoselection approach promises to enhance both the duration and expression level of a desired therapeutic gene in KC, by linking its expression to theMDR1selectable marker gene.